Roche’s Announcement regarding PiaSky (Approval in the EU for the Treatment of People with PNH)

TOKYO, August 27, 2024 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that Roche issued a Media Release regarding the Chugai originated pH-dependent binding humanized anti-complement (C5) monoclonal antibody PiaSky ® (generic name: crovalimab (genetical recombination)). The European Commission (EC) has approved PiaSky for the treatment of adults and adolescents (12 years of age or older with a weight of 40 kg and above) with paroxysmal nocturnal hemoglobinuria (PNH) who are new to and have been previously treated with C5 inhibitors. Please refer to the link below for details of the Roche’s Media Release: Roche’s PiaSky approved in the EU as the first monthly subcutaneous treatment for people with PNH https://www.roche.com/media/releases/med-cor-2024-08-27

The release as fetched from its publisher. chugai-pharm.co.jp ↗